Background and purpose: Anthracycline-containing regimens are widely used in advanced breast cancer. However, there is a need for new, non-anthracycline regimens that are active in patients for whom anthracyclines are contraindicated. The aim of this study was to determine the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs) and recommended doses of docetaxel and vinorelbine as first-line chemotherapy in patients with metastatic breast cancer. The pharmacokinetics of both drugs was also evaluated.
Summary
Background and purpose: Anthracycline-containing regimens are widely used in advanced breast cancer. However, there is a need for new, non-anthracycline regimens that are active in patients for whom anthracyclines are contraindicated. The aim of this study was to determine the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs) and recommended doses of docetaxel and vinorelbine as first-line chemotherapy in patients with metastatic breast cancer. The pharmacokinetics of both drugs was also evaluated.
Patients and methods: Thirty-four women with first-line metastatic breast cancer were treated with docetaxel, 60-100 mg/m 2 (day 1), and vinorelbine, 20-22.5 mg/m 2 (days 1 and 5), repeated every three weeks and administered on an outpatient basis.
Results: Two MTDs were determined: MTD1 was defined at the dose level using docetaxel 75 mg/m 2 , and vinorelbine 22.5 mg/m 2 ; DLT being a grade 3 stomatitis that was more related to the dose of vinorelbine than that of docetaxel. Therefore, the study continued with a fixed dose of vinorelbine, 20 mg/m 2 , and docetaxel 85-100 mg/m 2 . MTD2 was defined at the dose level combining docetaxel, 100 mg/m 2 . and vinorelbine, 20 mg/m 2 ; DLTs were grade 3 stomatitis and severe asthenia. Fluid retention was observed in 41% of patients but was never severe or a reason for patient discontinuation. In comparison with historical experience. Daflon 500® did not seem to increase the efficacy of the three-day corticosteroid premedication by further reducing the incidence or severity of fluid retention. No significant neurotoxicity was observed and no patient discontinued the study due to this site effect. Activity was observed at all dose levels and at all metastatic sites, with an overall response rate of 71% (95% CI: 52.0%-85.8%). The median time to progression was 31.4 weeks (95% CI: 12-48 weeks) and median survival was 15.6 months (95% CI: 2.6-26.6 months). The pharmacokinetics of docetaxel and vinorelbine were not modified between day 1 and day 3 when the two drugs were combined with the day 1 administration schedule used in this study.
Conclusion. The recommended doses for phase II studies are docetaxel, 75 mg/m 2 (day 1), plus vinorelbine, 20 mg/m
Introduction
Metastatic breast cancer remains an incurable disease and treatment is largely aimed at palliation. However, some extension of survival has been observed in certain patients with advanced disease following combination chemotherapy [1] . The anthracyclines, and doxorubicin in particular, have long been considered to be the most active agents in breast cancer, with reported response rates of around 50% [2] [3] [4] [5] [6] [7] . Combination regimens with doxorubicin are more effective than single-agent chemotherapy and the highest overall response rates (up to 60%) are currently achieved with anthracycline-containing regimens, such as cyclophosphamide and fluorouracil plus doxorubicin or epirubicin [8, 9] . However, some patients fail to respond to these therapies. Moreover, doxorubicin exhibits a cumulative cardiotoxicity, and the maximum recommended cumulative dose is 450-550 mg/m 2 [10] . An increasing number of patients with metastatic disease have already received anthracyclinebased adjuvant regimens for early breast cancer and, hence, the potential for further anthracycline salvage regimens is limited in these patients. There is, therefore, a need for new, non-anthracycline regimens for patients in whom these agents can no longer be administered. Two new agents, docetaxel (Taxotere®, Aventis Pharma) and vinorelbine (Navelbine®, Pierre Fabre Medicament) have demonstrated significant clinical activity in phase II and III trials of patients with metastatic breast cancer.
Single-agent docetaxel, 100 mg/m 2 , has produced high response rates of 54%-68% in phase II trials of first-line chemotherapy of metastatic breast cancer [11] [12] [13] [14] . Furthermore, the use of this agent as secondline chemotherapy is associated with response rates of 53%-58% [15] [16] [17] . These findings arise from phase II trials that included patients with anthracycline-resistant disease and indicate that incomplete clinical cross-resist-ance exists between docetaxel and anthracyclines [15] [16] [17] . Furthermore, in two trials conducted in metastatic breast cancer, single agent docetaxel has also been shown to be active at low doses, with overall response rates of 52% and 44% at doses of 75 mg/m 2 and 60 mg/m 2 , respectively [18, 19] .
Several phase III trials have established the position of docetaxel as the most active single agent in the treatment of breast cancer. The majority of these studies have been performed with patients who have failed prior anthracycline-containing regimens, including patients with anthracycline-resistant tumours. A large multicenter phase III randomised trial has demonstrated improved survival with docetaxel compared with combination therapy with mitomycin-C plus vinblastine, in patients with metastatic breast cancer who had progressed despite previous anthracycline-containing chemotherapy [20] . In similar patient populations, docetaxel has also produced similar or higher response rates when compared with combination therapy involving either 5-fluorouracil (5-FU) plus vinorelbine [21] or 5-FU plus methotrexate, respectively [22] . Docetaxel is the first drug to demonstrate significantly higher response rates than doxorubicin in patients with advanced breast cancer who had failed prior therapy with alkylating agents [23] .
Neutropenia, with a median day to nadir of eight days, is the main toxicity of docetaxel [24] . The drug is also associated with fluid retention, especially at cumulative doses of 400 mg/m 2 or higher [25] . Premedication with corticosteroids and antihistamines can reduce the incidence and severity of fluid retention but does not completely eliminate this adverse event [25, 26] . Daflon 500® is a flavonoid extract, containing mainly diosmin, which has been shown to reduce the incidence and severity of idiopathic peripheral edema associated with increased capillary permeability [27] . Preclinical tests on mice bearing B16 melanoma showed that adding diosmine to docetaxel did not result in any additional toxicity or in loss in antitumor activity compared to docetaxel alone. In the present study, Daflon 500® was added to standard premedication with corticosteroids and antihistamines in an attempt to further reduce the incidence and severity of docetaxel-induced fluid retention. Duration of grade IV for seven days is the main dose-limiting toxicity.
Vinorelbine is a semisynthetic vinca alkaloid, with a modification of the catharanthine moiety of vinblastine resulting in less neurotoxicity and major anti-tumor activity. Vinorelbine inhibits microtubule assembly, and blocks formation of the mitotic spindle apparatus at metaphase and prevents cell division. One of the most promising aspects of vinorelbine concerns the selective nature of its effects on non-neural microtubules [28] .
Single-agent vinorelbine, given at a weekly dose of 30 mg/m 2 , has produced response rates of 41%-60% in the first-line chemotherapy of metastatic breast cancer [29] [30] [31] [32] [33] [34] . These levels of response compare favorably with single agent response rates reported for anthracycline.
In second or third line the response rate is still 15%-37% [35, 36] . The response rate in patients previously treated with anthracycline for their MBC has been reported to be 33% [37] and vinorelbine showed significant activity in anthracycline refractory patients [38] , suggesting a possible non cross resistance. The dose-limiting toxicity of vinorelbine is neutropenia [39] [40] .
Given the significant single-agent clinical activity of both docetaxel and vinorelbine, preclinical studies have explored the feasibility of combining these two agents [41, 42] . Using subcutaneously implanted mammary tumors, MA 13/C and MA 16/C, in mice, intravenous docetaxel and vinorelbine have been evaluated alone and in combination. At the optimal doses, docetaxel and vinorelbine appear to have synergistic activity. Furthermore, the combination was well tolerated: it was possible to combine the full single-agent doses without increasing the toxicity to normal cells. These data provide the preclinical support for the present phase I-II trial of the combination of vinorelbine plus docetaxel.
The primary objectives of this trial were to determine the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs) and the recommended doses (RD) of docetaxel in combination with vinorelbine in patients with metastatic breast cancer who had not received previous chemotherapy for metastatic disease. Due to the fact that neutropenia induced by docetaxel has a median day to nadir of 8 days, we decided to give vinorelbine on days 1 and 5. In addition, the efficacy of a prophylactic premedication regimen of corticosteroids, antihistamine and Daflon 500® was evaluated in the prevention of fluid retention associated with docetaxel administration. The pharmacokinetics of both docetaxel and vinorelbine between day 1 and day 3, and the efficacy of the combination, were also evaluated.
Patients and methods

Patient selection
Thirty-four women with metastatic breast cancer were accrued into this phase I, dose-finding, single-center study. Eligible patients had histologically proven breast cancer with measurable and/or evaluable metastatic disease. Patients were excluded if they had received prior chemotherapy or > 2 hormonal therapy regimens for metastatic disease. Prior neoadjuvant and /or adjuvant chemotherapy, with or without anthracyclines, was permitted provided that at least 12 months had elapsed before study entry. Other eligibility criteria were WHO performance status < 2, absolute neutrophil count (ANC) ^2x IO 9 /1, platelet count > 100 x 10 9 /l, hemoglobin > 10 g/1, serum creatinine < 140 umol/dl, ASAT/ALAT $ 2 x upper normal limit (UNL), and bilirubin < 1.25 x UNL.
Exclusion criteria included: history of other malignancies (excluding non-melanoma skin cancer or well-excised cervical carcinoma), known CNS metastases, symptomatic peripheral neuropathy gradê 2, any poorly controlled coexisting medical conditions, prior therapy with taxanes or vinorelbine, concurrent treatment with other anticancer or experimental drugs.
The protocol was approved by an ethical committee and all patients provided written, informed consent before study entry.
Treatment
Vinorelbine, 20-22.5 mg/m 2 , was administered as a 30-minute intravenous infusion on days 1 and 5, followed by docetaxel, 60-100 mg/m 2 , as a 1-hour intravenous infusion on day 1 only. The treatment was repeated every three weeks and administered on an outpatient basis.
As prophylactic treatment for hypersensitivity reactions and fluid retention, all patients received oral dexamethasone, 8 mg (13 hours, 7 hours, and 1 hour before docetaxel administration, and 6, 12, 18, 24, 30, 36 and 42 hours after the infusion); oral cetirizine, 10 mg (7 hours before and 1 hour after docetaxel administration); oral ranitidine, 300 mg (once daily from 1 day before until 2 days after docetaxel administration); and oral Daflon 500® (twice daily from the first docetaxel infusion until the end of treatment).
Treatment was planned to continue for a maximum of six cycles unless there was evidence of disease progression, unacceptable toxicity, patient refusal, or stable disease with no improvement in symptoms after four cycles of treatment.
Dose-escalation and dose modifications
Five escalating dose levels of docetaxel and vinorelbine, without prophylactic granulocyte colony-stimulating factor (G-CSF), were planned (Table 1) . Doses were assigned at study entry and no dose escalation was permitted in individual patients. Three patients were treated at each dose level, with a two-week interval between entry of the first patient and the next two patients. Escalation to the next dose level was not attempted before at least two patients had completed > 2 cycles of treatment at the present dose level and had been observed for 2 weeks. If one out of three patients at a given dose level developed a DLT, three more patients were entered at the same dose level. The MTD was defined as the dose at which > 2 out of 3, or > 3 out of 6 patients developed DLT. In the case of a MTD in which the DLT was neutropenia, and/or its complications, further dose-escalation was planned to proceed with prophylactic G-CSF, starting from day 2 and continuing until there was evidence of hematological recovery (absolute granulocyte count > 1.0 x 10 9 /l). This was the case with the last five patients who entered at dose level VB.
Treatment was repeated every three weeks, provided blood cell counts had recovered and any non-hematologic toxicity had resolved to a level of grade < 1. Treatment was delayed by up to two weeks to allow recovery of ANC to > 1.5 x IO 9 /1 and/or platelets to 5= 100 x 10 9 /l. In the case of DLT or severe toxicity, treatment was discontinued until the toxicity had resolved to a level of grade < 1, and then restarted for the subsequent cycle at the dose below the previously administered dose level. Doses that had been reduced due to toxicity in individual patients were not subsequently escalated.
Definition of dose-limiting toxicity
Toxicity was graded according to the National Cancer Institute common toxicity criteria (NCI-CTC). DLT was defined as any grade 3-4 non-hematologic toxicity or any of the following hematologic toxicities: grade 4 neutropenia lasting >7 days, or no recovery (ANC < 1.5 IO 9 /1) at day 21; grade 3-4 neutropenia with fever U 38.5°C lasting > 3 days or grade 3-4 infection, grade 4 thrombocytopenia or no recovery (platelets 3= 100 x |0 9 /l) at day 21. or grade 3-4 bleeding.
Patient and treatment evaluation
Pretreatment evaluation included medical history; complete physical examination (vital signs, performance status and neurologic examination); tumor measurements (chest X-ray, abdominal CT scan or ultrasound and CT scans of all measurable evaluable and non-evaluable lesions, bone scan with MRI, CT scan or X-rays on hot spots); complete blood cell count (white blood cells with differential, platelets, hemoglobin); blood biochemistry and urinalysis; liver function tests and ECG. During treatment, patients were monitored for toxicity at least weekly throughout treatment. A complete blood cell count was performed twice weekly, or every two days in cases of febrile neutropenia, infection or grade 4 neutropenia. until recovery All other biochemistry tests were performed weekly A prospective neurological evaluation (including history, complete neurological examination and nerve conduction velocity) was performed in all treated patients by the same neurologist (J. P. Louboutin) at baseline, then after every two cycles of treatment, and during the follow-up period or when clinically indicated. Tumor measurements were repeated every two cycles, or every cycle in case of clinically monitored target lesions. Tumor response was assessed according to the WHO criteria [43] and all patients were reviewed for response by an independent radiologist.
The duration of partial response (PR) was calculated from the start of treatment until the first documentation of progressive disease (PD). while the duration of complete response (CR) was from the first time the CR was documented. Time to first response and time to progression were calculated from the first administration of the drugs to the first occurrence of response and first progression, respectively. Patients who had received further antitumor treatment before progression were censored at the start of the new treatment. Survival was calculated from the date of the first administration of the study drugs until death Patients who had received at least two cycles of therapy were considered evaluable for response unless disease progression was noted prior to cycle 2. in which case the patient was regarded as having early progression.
Pharmacokinetic analysis
The pharmacokinetics of docetaxel and vinorelbine were evaluated during the first cycle only. For docetaxel. 13 blood samples were collected (immediately before the infusion. 30 minutes after the start of infusion, and at 5, 15, 45, 90 minutes, and 3, 5, 8. 12. 24. 48. 72 hours after the end of the infusion). Plasma docetaxel concentrations were measured at Aventis. Antony, France using high performance liquid chromatography (HPLC) on a C18 reversed-phase column with UV detection at 225 nm; the quantification limit of this method, using a 1 ml plasma sample, was 10 ng/ml [44] , Pharmacokinetic parameters were estimated by nonlinear least square regression analysis using WinNonlin software (Scientific Consulting Inc., USA) and a two-or three-compartment model with first-order elimination.
For vinorelbine. 14 blood samples were collected (immediately before the infusion. 15 and 25 minutes after the start of infusion, and at 5, 15, 30 minutes, and 1, 2. 4. 9. 13. 25. 49. 73 hours after the end of the infusion). Plasma vinorelbine concentrations were measured at the Rene Gauducheau Centre, Saint-Herblain, France, using reversedphase HPLC with UV detection at 268 nm; the quantification limit of this method, using a 1 ml plasma sample, was 2.5 ng/ml [45] . Pharmacokinetic parameters were estimated by nonlinear least square regression analysis using Micropharm-K software [46] and a two-or three-compartment open model with first-order elimination For both drugs, the analysis focused on area under the plasma concentration-time curve (AUC) and total body clearance (CL). The terminal half-life (t, /:/ J and volume of distribution at steady-state (Vss) were also estimated.
Results
Patient characteristics
Thirty-four patients with metastatic breast cancer who had not received previous chemotherapy for metastatic disease were entered into the study ( Table 2 ). The median WHO performance score was 0. The median number of metastatic sites was 2, and 26 patients (76%) had visceral disease, with liver metastases in 18 patients (53%). The majority of patients (82%) had received adjuvant chemotherapy before study entry, and 80% had received an adjuvant anthracycline-based regimen with a median cumulative dose of doxorubicin, or equivalent, of 167 mg/m 2 (range 83-333).
All registered patients were treated and evaluated for safety; three patients were not evaluable for response, mainly due to the lack of complete tumor assessment during the study. 
Chemotherapy administration
A total of 197 cycles of docetaxel and vinorelbine were administered during the study. The median number of cycles was six (range 1-8) at all dose levels except level III (n -5) (Table 3) . When all dose levels were combined, the median cumulative dose of docetaxel was 492 mg/m 2 (range 100-802) and that of vinorelbine was 240 mg/m 2 (range 40-320). The median relative dose intensities (RDIs) of docetaxel and vinorelbine were 0.98 (range 0.71-1.01) and 0.99 (range 0.78-1.01), respectively. Considering each dose level separately, the median RDIs for both drugs were > 0.98 at all dose levels, except at level III (75/22.5 mg/m 2 ), where the median RDI of vinorelbine (0.87) and docetaxel (0.93) were both reduced, and levels V (100/20 mg/m 2 ) where the RDI of docetaxel was reduced (0.92). These two dose levels were found to be the MTDs of the combination (see below).
The majority of cycles were given every 3 weeks as planned, with only a few (2.5%) delayed by 3-7 days (5 cycles) or by > 7 days (2 cycles); febrile neutropenia and stomatitis were the main reasons for these delays.
Overall, the majority of cycles (89%) were administered at the initially planned doses. Among the 20 cycles (10%) that were given at reduced doses, the dose of docetaxel was reduced in 15 cycles, while the dose of vinorelbine was decreased in 5 cycles. Non-hematological toxicities, or a combination of both hematological and non-hematological toxicities, were the main reasons for dose modifications.
Toxicity
All 34 treated patients were evaluable for safety. Grade 4 neutropenia was the most frequent adverse event observed during this study and occurred in all patients and in 93% of cycles (Table 4) . It was, however, brief in duration, with a median duration of five days. Overall, febrile neutropenia (grade 4 neutropenia with grade ^ 2 fever requiring intravenous antibiotics and /or patient hospitalization) was observed in nine patients (26%) and in 9% of cycles, respectively ( Table 5 ). The highest rate was noted at dose level III (75/22.5 mg/m 2 ), where three out of the four patients treated developed febrile neutropenia and 28% of cycles were complicated by this event. No febrile neutropenia was observed among the five patients who received prophylactic G-CSF.
Grade 3-4 infections occurred in three patients (one at dose level II and two at dose level V), two of whom died; both deaths were considered to be drug-related. These two patients had baseline impaired liver function tests, which are known to be associated with a high risk of severe toxicity, toxic death and treatment discontinuation due to toxicity. Both patients had elevated AS AT/A LAT values at registration, but still within protocol limits. However, the study treatment was delayed by several days, and liver function tests done after first study drug infusion showed that ASAT/ALAT values had worsened rapidly during the delay and that they were now above protocol limits. As the patients were doing well and showed benefit, study treatment was continued.
Although anemia was frequently observed during the study, 26% of patients had grade 1, 2 or 3 anemia at baseline. Nine patients (26%) had grade 3 anemia and two patients (6%, both at dose level V), had grade 4 anemia. Thrombocytopenia occurred rarely (Table 4) . Grade 3 episodes were observed in only 9% of patients (two patients at dose level II and one patient at dose level V).
Non-hematological toxicities were observed less frequently than hematological toxicities (Table 6) . Diarrhea, nausea and vomiting were observed at all dose levels. However, these events were generally mild in nature (grade 1-2). Stomatitis was a common adverse event. It occurred in 31 patients (91%) and was severe (grade 3) in 10 patients (29%). At dose level III (with 22.5 mg/m 2 of vinorelbine), grade 3 stomatitis occurred in two out of four (50%) patients and in 16% of cycles. This was much higher than dose level II, with the same dose of docetaxel but a lower dose of vinorelbine, where only one out of six (17%) patients experienced grade 3 stomatitis. Moreover, at subsequent dose levels, when the dose of vinorelbine was reduced to 20 mg/m 2 , grade 3 stomatitis occurred in 7 out of 21 (33%) patients and in only 6% of cycles despite an increase in the dose of docetaxel to 85 or 100 mg/m 2 (levels IV, V and VB, respectively). This trend was also observed when the analysis was performed at the first cycle only. These data suggested that the incidence and severity of stomatitis are more related to the use of a higher dose of vinorelbine (22.5 mg/m 2 ) than to the docetaxel dose, and dose level III was, therefore, considered to be the MTD1 for vinorelbine; the DLT being grade 3 stomatitis. The protocol was subsequently amended to evaluate further dose levels of docetaxel (85-100 mg/m 2 ) in combination with a lower and fixed dose of vinorelbine of 20 mg/m 2 . Asthenia was the major chronic non-hematologic toxicity. It was reported in 33 patients (97%) and was severe in 14 patients (41%). Asthenia appeared to be related to the dose of docetaxel since it was observed in all 11 patients treated with docetaxel, 100 mg/m 2 , and was severe in 8 of these, whereas only 6 of the 23 patients who received docetaxel at ^ 85 mg/m 2 developed severe dose-limiting asthenia. According to these observations, MTD2 was considered to have been reached at dose level V, with severe asthenia and grade 3 stomatitis being the DLTs.
Neurological function was evaluated for all patients. Although neurosensory toxicity was common (94% of patients), no grade 3 symptoms were observed and no patient discontinued due to neurotoxicity. Grade 1 peripheral neuropathy (manifested as asymptomatic loss of deep tendon reflex) was observed in 91% of patients and was grade 2 in only one patient. Two patients reported grade 1 neuromotor toxicity.
With a median cumulative docetaxel dose of 502 mg/m 2 (range 195-802), fluid retention occurred in 41% of patients (mild in 13, moderate in 1 patient) but no patient discontinued treatment as a result of this adverse event. The median cumulative docetaxel dose to onset of fluid retention was 601 mg/m 2 (range 75-680+). In comparison with historical experience, Daflon 500® did not increase the efficacy of the standard three-day corticosteroid premedication [47] .
The other docetaxel-specific toxicities such as skin toxicity or nail disorders were infrequently observed and rarely severe. 
Pharmcicokinetics
The pharmacokinetics of docetaxel and vinorelbine were evaluated in 29 out of 34 patients (Table 7) . However, one and seven patients were excluded from the docetaxel and vinorelbine pharmacokinetic analyses, respectively, because of chromatographic interferences. A marked inter-patient variability was observed for Vss and terminal half-life (ti /2Z ) for both compounds. However, the main pharmacokinetic parameters of docetaxel were relatively stable across the vinorelbine dose range 
Efficacy
Among the 31 patients who were eligible and evaluable for response, 1 complete response (CR) and 21 partial responses (PR) were observed, giving an overall response rate of 71% (95% CI: 52.0-85.8%). The remaining nine patients had stable disease and no patient had progressive disease as best overall response. The combination was active at all dose levels and at all metastatic sites. In patients with visceral and liver metastases, response rates of 78% and 86% were achieved respectively.
Prior adjuvant chemotherapy with anthracyclines did not seem to compromise the activity of the combination: objective responses were observed in 19 of 26 patients (73%) who had previously received anthracyclines, compared with 3 of 5 (60%) who had not.
The median time to first response was 12 weeks (range 5-19+) and the median duration of response in responding patients was 30 weeks (range . The median time to disease progression was 31.4 weeks (range . With a median follow-up of 18.3 months, the median survival for the intent-to-treat patient population was 15.6 months (range 2.6-26.6).
Discussion
Docetaxel and vinorelbine are both myelosuppressive agents and increased hematotoxicity might be expected when these drugs are administered in combination. The starting doses for the combination in this study were, therefore, lower than those recommended for the respective single agents, but still associated with acceptable levels of activity. Nonetheless, all patients experienced neutropenia with the docetaxel-vinorelbine combination. Other common adverse events were anemia, asthenia and stomatitis.
The highest incidence of febrile neutropenia was observed with docetaxel 75 mg/m 2 , plus vinorelbine 22.5 mg/m 2 , and occurred in 3 out of 4 patients, and in 28% of cycles. Similarly, the highest incidence of grade 3-4 stomatitis was observed at this dose level III. Therefore, dose III level (docetaxel 75 mg/m 2 plus vinorelbine 22.5 mg/m 2 ) was considered to be the MTD1 of the docetaxel-vinorelbine combination, the DLTs being grade 3 stomatitis. At that moment, preliminary results from combination studies showed that when vinorelbine was used in combination with hematotoxic drugs such as antracyclines, neutropenia is the dose limiting toxicity and only less than 25 mg/m 2 on day 1 and 8 can be administered without major toxicity [48, 49] . Therefore, after this MTD, we decided that it was not appropriate to increase the vinorelbine dose, and we decided to lower it to 20 mg/m 2 so as to investigate further dose levels by increasing the docetaxel dose. This was further supported by a recent study which showed that when vinorelbine 30 mg/m 2 day 1 and 8 was combined with paclitaxel 135 mg/m 2 day 1, the actual dose of vinorelbine administered after six cycles was only 62% of that initially planned, i.e., 19 mg/m 2 [50] . Three patients developed severe infection (two at dose level V, and one at dose level II), two of whom died. Both patients who died had impaired liver function tests (ASAT 5 x and 2.3 x UNL ) at baseline, which are associated with a high risk of severe toxicity, toxic death and treatment discontinuation due to toxicity [51] .
Although these abnormal liver function tests were not within the exact limits defined by the pharmacokinetic/ pharmacodynamic analysis reported by Bruno et al. [52] , patients with isolated elevation of transaminases above 1.5 times the UNL appeared to be at high risk of severe toxicity in this study.
Asthenia was observed in all patients and its severity appeared to be related to the dose of docetaxel. The incidence of severe, dose-limiting asthenia was much lower at docetaxel doses of ^ 85 mg/m 2 (6 of 23 patients, 26%) than 100 mg/m 2 (8 of 11 patients, 72.8%). Therefore, dose level V was considered to be MTD 2 of the combination, with the DLTs being severe asthenia and grade 3 stomatitis.
Despite a median cumulative docetaxel dose of 492 mg/m 2 (range 100-802 mg/m 2 ), fluid retention occurred in only 41% of patients but in no instance was it severe or a reason for treatment discontinuation. A comparison with historical data reported in the literature [44] , showed that neither antihistamines nor Daflon 500® reduced the incidence of fluid retention; in addition, it is known that the three-day corticosteroid premedication used in this study was as effective as a five-day regimen reported elsewhere [53] . Thus, it appears that the reduction of fluid retention in this trial may be attributed to the three-day corticosteroid premedication regimen alone.
Several case reports have recently been published in which an association has been demonstrated between docetaxel-containing chemotherapy and the development of a severe colitis-like syndrome, in patients with metastatic breast cancer [54] . This complication was reported to be more frequent when docetaxel was combined with vinorelbine than with other agents. However, similar symptoms were not observed in any patient in this study, even at the highest dose levels. In addition, despite the combined administration of two antitubulin agents, which are associated with the development of neurotoxicity, no significant neurotoxicity was observed in this study and no patient discontinued because of this adverse event.
The pharmacokinetic data obtained in this study were compared with those observed in two phase I trials in which single-agent docetaxel was administered as one-to two-hour intravenous infusion, at doses ranging from 20-115 mg/m 2 [55] . In our study, the pharmacokinetic parameters between day 1 and day 3 were comparable to those described when docetaxel is administered alone. Thus, the addition of vinorelbine (with or without G-CSF) does not seem to influence the pharmacokinetics of docetaxel between day 1 and day 3 when the two drugs are given together, according to the day 1 administration schedule used in this study. Similarly, docetaxel does not appear to modify the pharmacokinetics of vinorelbine between day 1 and day 3 with this administration modus, even when G-CSF is added to the regimen [56] .
Although efficacy was not a primary endpoint in this study, antitumor activity was observed at each dose level. Cyclophosphamide plus doxorubicin and fluorouracil is one of the most active and commonly used polychemotherapy regimens and produces overall response rates of 50%-82% in patients with metastatic breast cancer [8] . In our trial, the highest activity of the docetaxel-vinorelbine combination was observed at dose levels of 85 mg/m 2 and 20 mg/m 2 , respectively, with 1 complete and 7 partial responses in 10 evaluable patients. Moreover, despite the fact that 80% of our patient population had been exposed to prior adjuvant anthracyclines, the combination produced an overall response rate of 73%.
Based on the above observations, our recommended dose for this combination is docetaxel 85 mg/m 2 plus vinorelbine 20 mg/m 2 , administered every three weeks without G-CSF. An ongoing phase II multicenter trial is currently further exploring the efficacy and tolerability of this dose level. Preliminary evaluation of the first 18 patients has shown a high incidence of febrile neutropenia and, therefore, the dose of docetaxel has been reduced to 75 mg/m 2 for the remainder of the trial (P. Fumoleau, personal communication April 1998). The combination of docetaxel 75 mg/m 2 plus vinorelbine 20 mg/m 2 is better tolerated with no apparent loss of efficacy associated with the lower dose of docetaxel. These recent data suggest that the recommended dose of the combination should be modified to docetaxel 75 mg/m 2 on day 1, plus vinorelbine 20 mg/m 2 on days 1 and 5, for the treatment of metastatic breast cancer. This regimen can be administered on an outpatient basis without the requirement for prophylactic G-CSF. Once the activity of the combination has been confirmed in a larger patient population, the combination of docetaxel and vinorelbine may have a role either as first-line chemotherapy in patients with metastatic breast cancer in whom further anthracycline-containing chemotherapy cannot be used, or as second-line chemotherapy after failure of anthracycline-based therapy.
